{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:49:20Z","timestamp":1793933360234,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lanepe.2025.101476","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:34:51Z","timestamp":1758972891000},"page":"101476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-0553","authenticated-orcid":false,"given":"Alessandro","family":"Cagol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schaedelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Pretzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4917-8761","authenticated-orcid":false,"given":"Cristina","family":"Granziera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10130","key":"10.1016\/j.lanepe.2025.101476_bib1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib2","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib3","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"14","key":"10.1016\/j.lanepe.2025.101476_bib5","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1177\/1352458513488231","article-title":"Clinical impact of early brain atrophy in clinically isolated syndromes","volume":"19","author":"P\u00e9rez-Miralles","year":"2013","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101476_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jnnp.2007.124123","article-title":"Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters","volume":"79","author":"Minneboo","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib7","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/brain\/awx250","article-title":"Long-term disability progression in primary progressive multiple sclerosis: a 15-year study","volume":"140","author":"Rocca","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149685","article-title":"The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"11","author":"Branger","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101476_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/1352458517690272","article-title":"Indirect comparisons of treatment effects: network meta-analyses","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Software"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101476_bib15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","article-title":"Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS","volume":"53","author":"Rudick","year":"1999","journal-title":"Neurology"},{"issue":"9139","key":"10.1016\/j.lanepe.2025.101476_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon \u03b2-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"Kappos","year":"1998","journal-title":"Lancet"},{"issue":"Pt 11","key":"10.1016\/j.lanepe.2025.101476_bib17","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/brain\/123.11.2256","article-title":"The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis","volume":"123","author":"Molyneux","year":"2000","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.lanepe.2025.101476_bib18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101476_bib19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101476_bib20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"issue":"17","key":"10.1016\/j.lanepe.2025.101476_bib21","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101476_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101476_bib23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/1352458509106937","article-title":"A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis","volume":"15","author":"Montalban","year":"2009","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.lanepe.2025.101476_bib26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib27","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101476_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.0000000000001360","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study","volume":"84","author":"Miller","year":"2015","journal-title":"Neurology"},{"issue":"9856","key":"10.1016\/j.lanepe.2025.101476_bib30","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.lanepe.2025.101476_bib31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101476_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101476_bib33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101476_bib34","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00415-014-7412-x","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study","volume":"261","author":"Arnold","year":"2014","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101476_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101476_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10023","key":"10.1016\/j.lanepe.2025.101476_bib37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101476_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1352458517690269","article-title":"Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets","volume":"24","author":"De Stefano","year":"2018","journal-title":"Mult Scler"},{"issue":"10127","key":"10.1016\/j.lanepe.2025.101476_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib45","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101476_bib46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2020.2950","article-title":"Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"78","author":"Cree","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib49","article-title":"Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis: a randomized, controlled trial","volume":"8","author":"Chow","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101476_bib50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101476_bib51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101476_bib52","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101476_bib53","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101476_bib55","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","article-title":"Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis","volume":"79","author":"Cagol","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101476_bib56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101476_bib57","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101476_bib58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101476_bib59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101476_bib61","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability in vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib62","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207768","article-title":"Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS","volume":"102","author":"Cagol","year":"2024","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101476_bib63","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101476_bib64","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain"},{"issue":"24","key":"10.1016\/j.lanepe.2025.101476_bib65","doi-asserted-by":"crossref","first-page":"e2099","DOI":"10.1212\/WNL.0000000000005685","article-title":"The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis","volume":"90","author":"Scalfari","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101476_bib67","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1212\/WNL.0000000000005853","article-title":"Spinal cord volume loss: a marker of disease progression in multiple sclerosis","volume":"91","author":"Tsagkas","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib68","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","article-title":"Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis","volume":"91","author":"Bischof","year":"2022","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.25150","article-title":"Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease","volume":"83","author":"Azevedo","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis","volume":"83","author":"Eshaghi","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101476_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/brain\/awv337","article-title":"Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant","volume":"139","author":"Steenwijk","year":"2016","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101476_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200299","article-title":"Advanced quantitative MRI unveils microstructural thalamic changes reflecting disease progression in multiple sclerosis","volume":"11","author":"Cagol","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101476_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nic.2017.01.002","article-title":"Brain atrophy in multiple sclerosis: clinical relevance and technical aspects","volume":"27","author":"Sastre-Garriga","year":"2017","journal-title":"Neuroimaging Clin N Am"},{"issue":"19","key":"10.1016\/j.lanepe.2025.101476_bib74","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lanepe.2025.101476_bib75","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101476_bib76","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/01.WNL.0000120663.85143.B3","article-title":"Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis","volume":"62","author":"Sormani","year":"2004","journal-title":"Neurology"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:58:26Z","timestamp":1773363506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225002686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":76,"alternative-id":["S2666776225002686"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101476","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101476"}}